Treatment of hepatorenal syndrome Octreotide vs. Midodrine vs. Norepinephrine as part of triple therapy

Osman Mohamed Osman;

Abstract


Background: hepatorenal syndrome is a serious complication of liver cirrhosis. Splanchnic vasodilatation is the main pathology. Vasoconstrictors are used as treatment aiming at reversal of renal dysfunction.
Methods: thirty patients with hepatorenal syn


Other data

Title Treatment of hepatorenal syndrome Octreotide vs. Midodrine vs. Norepinephrine as part of triple therapy
Other Titles علاج متلازمة الفشل الكبدي الكلوي مقارنة بين أوكتريوتايد، ميدودرين و نورابينفرين كجزء من العلاج الثلاثي
Authors Osman Mohamed Osman
Keywords Treatment of hepatorenal syndrome Octreotide vs. Midodrine vs. Norepinephrine as part of triple therapy
Issue Date 2012
Description 
Background: hepatorenal syndrome is a serious complication of liver cirrhosis. Splanchnic vasodilatation is the main pathology. Vasoconstrictors are used as treatment aiming at reversal of renal dysfunction.
Methods: thirty patients with hepatorenal syn

Attached Files

File SizeFormat
111271R7272.pdf258.12 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 2 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.